ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical D... (own as 'CCR9' which is predominantly exp...)

ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development

Date:10/15/2008

own as 'CCR9', which is predominantly expressed by inflammatory T cells. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn's disease, ulcerative colitis and other inflammatory disorders of the gastrointestinal system. This chemokine receptor is known to play a pivotal role in the migration of inflammatory T cells to the digestive tract, resulting in the persistent inflammation and tissue damage underlying these diseases. CCR9 is one of four defined chemokine and chemoattractant receptor targets covered under a 2006 alliance between ChemoCentryx and GlaxoSmithKline's Center of Excellence for External Drug Discovery (CEEDD), under which GSK has option rights to license certain product candidates.

About ChemoCentryx

ChemoCentryx, Inc., is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a network of secreted chemokine molecules, or ligands, and cell surface receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, is currently in a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. CCX025, also a CCR9 antagonist, is in a Phase I clinical trial. Additional clinical programs include the development of CCX140, which targets the CCR2 receptor, currently in a Phase I clinical trial and intended for subsequent development to treat diseases such as vascular restenosis, Type 2 diabetes and/or multiple sclerosis; and CC
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
2. Will New Technological Advances Offer Fresh Capabilities for Commercialization and Enhance BTL Investments?
3. Ardea Biosciences Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
4. New molecular imaging techniques may lead to advances in disease treatment
5. Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs
6. Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing
7. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
8. Human Genome Sciences Advances Oncology Portfolio
9. ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
10. Genetic Engineering & Biotechnology News reports on advances in miRNA
11. Malaysia Genome Institute Advances Bioinformatics Research Using SGI Technology

Post Your Comments:

ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical D...(own as 'CCR9' which is predominantly exp...)